News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting

EP. 1: ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

EP. 2: ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

EP. 3: ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Trending on OncLive

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications

Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer

Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC

Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer